Last reviewed · How we verify
VAX102 [Flagellin.HuM2e]
VAX102 [Flagellin.HuM2e] is a Biologic drug developed by VaxInnate Corporation. It is currently in Phase 1 development.
At a glance
| Generic name | VAX102 [Flagellin.HuM2e] |
|---|---|
| Sponsor | VaxInnate Corporation |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VAX102 [Flagellin.HuM2e] CI brief — competitive landscape report
- VAX102 [Flagellin.HuM2e] updates RSS · CI watch RSS
- VaxInnate Corporation portfolio CI
Frequently asked questions about VAX102 [Flagellin.HuM2e]
What is VAX102 [Flagellin.HuM2e]?
VAX102 [Flagellin.HuM2e] is a Biologic drug developed by VaxInnate Corporation.
Who makes VAX102 [Flagellin.HuM2e]?
VAX102 [Flagellin.HuM2e] is developed by VaxInnate Corporation (see full VaxInnate Corporation pipeline at /company/vaxinnate-corporation).
What development phase is VAX102 [Flagellin.HuM2e] in?
VAX102 [Flagellin.HuM2e] is in Phase 1.
Related
- Manufacturer: VaxInnate Corporation — full pipeline